{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": "CDC_Influenza_vaccines",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 3
  },
  "completeness_stats": {
    "existing_evidence": 3,
    "new_evidence_found": 3,
    "total_evidence": 3
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "RIV4 (recombinant HA vaccine) Flublok Quadrivalent (Sanofi Pasteur) 0.5-mL PFS \u226518 yrs 45 \u00b5g/0.5 mL IM",
      "relevance_explanation": "This quote shows that Flublok Quadrivalent contains 45 \u00b5g of hemagglutinin (HA) antigen per 0.5 mL dose, which is three times the 15 \u00b5g/0.5 mL dose found in standard-dose flu vaccines, directly supporting the first part of the claim."
    },
    {
      "id": 2,
      "quote": "Fluzone Quadrivalent (Sanofi Pasteur) 0.5-mL PFS \u22656 mos 15 \u00b5g/0.5 mL IM",
      "relevance_explanation": "This quote provides the HA antigen content for a standard-dose flu vaccine (15 \u00b5g/0.5 mL), which can be directly compared to Flublok's 45 \u00b5g/0.5 mL, supporting the claim that Flublok contains 3x the HA antigen content."
    },
    {
      "id": 3,
      "quote": "RIV4 (recombinant HA vaccine) ... has been linked to greater immunogenicity vs standard-dose flu vaccines.",
      "relevance_explanation": "This statement directly links the recombinant HA vaccine (RIV4, which is Flublok) to greater immunogenicity compared to standard-dose flu vaccines, supporting the second part of the claim."
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}